Clarity Pharmaceuticals Ltd
ASX: CU6.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michelle Parker
- Employees
- 50
- Headquarters
- Sydney, Australia
- IPO year
- 2021
- Market cap
- A$1.1B
- Website
- https://www.claritypharmaceuticals.com
Loading CU6…
Loading profile data…Frequently asked questions about CU6
What does Clarity Pharmaceuticals Ltd (CU6.AX) do?
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The...
Where does CU6.AX trade?
Clarity Pharmaceuticals Ltd (CU6.AX) trades on the Australian Securities Exchange.
What sector is CU6.AX in?
Clarity Pharmaceuticals Ltd (CU6.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clarity Pharmaceuticals Ltd?
Michelle Parker is the chief executive officer of Clarity Pharmaceuticals Ltd (CU6.AX).
Where is Clarity Pharmaceuticals Ltd headquartered?
Clarity Pharmaceuticals Ltd is headquartered in Australia.
Does CU6.AX pay a dividend?
Clarity Pharmaceuticals Ltd (CU6.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CU6.AX go public?
Clarity Pharmaceuticals Ltd (CU6.AX) completed its initial public offering in 2021.